AWM
CMMB

Activest Wealth Management’s Chemomab Therapeutics CMMB Stock Holding History

Activest Wealth Management’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,900
Closed -$24.3K – 359
2022
Q4 		$24.3K Hold
1,900
– – 0.01% 242
2022
Q3 		$19K Buy
+1,900
New +$24.5K 0.01% 259

Other funds holding CMMB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $8.11B AUM 24.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Activest Wealth Management's CMMB Position: Q1 2023 in Review

Activest Wealth Management sold out of Chemomab Therapeutics (CMMB) in Q1 2023, closing a stake of 1,900 shares — an estimated $24.3K sold.

Activest Wealth Management first reported a position in CMMB in Q3 2022 and held it in 2 quarters. The position peaked at $24.3K in Q4 2022. 14 funds tracked by Wall St. Rank hold CMMB as of Q1 2023.

  • Activest Wealth Management reported no remaining Chemomab Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Activest Wealth Management sold 1,900 Chemomab Therapeutics shares in Q1 2023, an estimated $24.3K.
  • Activest Wealth Management first reported a position in Chemomab Therapeutics in Q3 2022 and held it in 2 quarters.
  • Activest Wealth Management's Chemomab Therapeutics position peaked at $24.3K in Q4 2022.
  • 14 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q1 2023.

Based on Activest Wealth Management's 13F filing for Q1 2023, filed 18 Apr 2023.